Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy

Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma

(2015) Mario Venza et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

The BCL-2 protein family, BH3-mimetics and cancer therapy

(2015) A R D Delbridge et al.   CELL DEATH AND DIFFERENTIATION

The requirement of histone modification by PRDM12 and Kdm4a for the development of pre-placodal ectoderm and neural crest in Xenopus

(2015) Shinya Matsukawa et al.   DEVELOPMENTAL BIOLOGY

Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma

(2015) Peter Hersey et al.   Future Oncology

The Chromatin-Modifying Enzyme Ezh2 Is Critical for the Maintenance of Regulatory T Cell Identity after Activation

(2015) Michel DuPage et al.   IMMUNITY

Inhibiting STAT5 by the BET Bromodomain Inhibitor JQ1 Disrupts Human Dendritic Cell Maturation

(2015) Patricia A. Toniolo et al.   JOURNAL OF IMMUNOLOGY

Polycomb Repressive Complex 2 Confers BRG1 Dependency on theCIITALocus

(2015) Mohamed Abou El Hassan et al.   JOURNAL OF IMMUNOLOGY

Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas

(2015) Jinhua Wang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The Role of BPTF in Melanoma Progression and in Response to BRAF-Targeted Therapy

(2015) Altaf A. Dar et al.   JNCI-Journal of the National Cancer Institute

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma

(2015) James S Wilmott et al.   MODERN PATHOLOGY

Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma

(2015) Chiara Vardabasso et al.   MOLECULAR CELL

Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation

(2015) K.V. Woan et al.   Molecular Oncology

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

(2015) Benjamin G Bitler et al.   NATURE MEDICINE

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity

(2015) K Cao et al.   ONCOGENE

BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model

(2015) Daniele Perna et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition

(2015) Katrin Liffers et al.   Targeted Oncology

The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors

(2015) Daniel Zingg et al.   Nature Communications

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state

(2015) Annelien Verfaillie et al.   Nature Communications

Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth

(2015) Anthony M. Barsotti et al.   Oncotarget

A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification

(2015) Matteo Dugo et al.   Oncotarget

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes

(2015) Jessamy C. Tiffen et al.   Oncotarget

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling

(2015) Anja Heinemann et al.   Oncotarget

The Role of BPTF in Melanoma Progression and in Response to BRAF-Targeted Therapy

(2015) Altaf A. Dar et al.   JNCI-Journal of the National Cancer Institute

Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies

(2015) Patrice E. Herait et al.   CANCER RESEARCH

Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB

(2015) Kavitha Gowrishankar et al.   PLoS One

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma

(2015) Francesco Spagnolo et al.   Oncotarget

HDAC inhibitors and immunotherapy; a double edged sword?

(2015) Michiel Kroesen et al.   Oncotarget

Modulation of BRAHMA expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation

(2014) Aanchal Mehrotra et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

MITF in melanoma: mechanisms behind its expression and activity

(2014) Mariusz L. Hartman et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

SWI/SNF Chromatin Remodeling Enzymes in Melanocyte Differentiation and Melanoma

(2014) A. Mehrotra et al.   CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP

(2014) Isabella Venza et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review)

(2014) GIULIA GRAZIA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Decreased Expression of the Chromatin Remodeler ATRX Associates with Melanoma Progression

(2014) Zulekha A. Qadeer et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells

(2014) Stuart J. Gallagher et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Melanoma epigenetics: novel mechanisms, markers and medicines

(2014) Jonathan J Lee et al.   LABORATORY INVESTIGATION

FOXD3 Modulates Migration through Direct Transcriptional Repression of TWIST1 in Melanoma

(2014) M. B. Weiss et al.   MOLECULAR CANCER RESEARCH

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells

(2014) Aaron Arvey et al.   NATURE IMMUNOLOGY

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy

(2014) Nethia Mohana-Kumaran et al.   Pigment Cell & Melanoma Research

Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151

(2014) Stuart J. Gallagher et al.   Pigment Cell & Melanoma Research

EZH2: an emerging role in melanoma biology and strategies for targeted therapy

(2014) Jessamy Tiffen et al.   Pigment Cell & Melanoma Research

Histone H3.3 and its proteolytically processed form drive a cellular senescence programme

(2014) Luis F. Duarte et al.   Nature Communications

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

(2014) D. J. Konieczkowski et al.   Cancer Discovery

Trichostatin A Suppresses EGFR Expression through Induction of MicroRNA-7 in an HDAC-Independent Manner in Lapatinib-Treated Cells

(2014) Chih-Yen Tu et al.   Biomed Research International

Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function

(2014) D. J. L. Wong et al.   Cancer Immunology Research

The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells

(2014) Dominique N Lisiero et al.   Journal for ImmunoTherapy of Cancer

Effects of Epithelial to Mesenchymal Transition on T Cell Targeting of Melanoma Cells

(2014) Katherine Woods et al.   Frontiers in Oncology

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

(2013) Alexander Roesch et al.   CANCER CELL

Anti-apoptotic proteins on guard of melanoma cell survival

(2013) Mariusz L. Hartman et al.   CANCER LETTERS

BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy

(2013) M. F. Segura et al.   CANCER RESEARCH

Histone variants: emerging players in cancer biology

(2013) Chiara Vardabasso et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma

(2013) Christopher S. McKee et al.   EXPERIMENTAL DERMATOLOGY

Is Mcl-1L the new anti-apoptotic effector of B-RAFV600Ein melanoma?

(2013) Daniele Bergamaschi   EXPERIMENTAL DERMATOLOGY

Toxicological and metabolic considerations for histone deacetylase inhibitors

(2013) Joanna Fraczek et al.   Expert Opinion on Drug Metabolism & Toxicology

Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation

(2013) D V Chan et al.   GENES AND IMMUNITY

Epigenetics of melanoma: implications for immune-based therapies

(2013) Elisabetta Fratta et al.   Immunotherapy

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

(2013) Ethan V. Abel et al.   JOURNAL OF CLINICAL INVESTIGATION

BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses

(2013) A. C. Belkina et al.   JOURNAL OF IMMUNOLOGY

The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity

(2013) David M. Woods et al.   MELANOMA RESEARCH

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

(2013) Cory M. Johannessen et al.   NATURE

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRG1 promotes survival of UV-irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene

(2013) Srinivas V. Saladi et al.   Pigment Cell & Melanoma Research

The Human Melanoma Side Population Displays Molecular and Functional Characteristics of Enriched Chemoresistance and Tumorigenesis

(2013) Jasper Wouters et al.   PLoS One

Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma

(2013) P. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells

(2013) M-C Chen et al.   Cell Death & Disease

Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3

(2013) F Lai et al.   Cell Death & Disease

PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma

(2013) Yan Ye et al.   Nature Communications

Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors

(2013) Kevin Cronin et al.   Human Vaccines & Immunotherapeutics

Heterogeneity of expression of epithelial–mesenchymal transition markers in melanocytes and melanoma cell lines

(2013) Ji Eun Kim et al.   Frontiers in Genetics

Immunotherapy of cancer in 2012

(2012) John M. Kirkwood et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors

(2012) Ken Saijo et al.   CANCER SCIENCE

Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma

(2012) Christine Guo Lian et al.   CELL

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

The tumor suppressor HINT1 regulates MITF and β-catenin transcriptional activity in melanoma cells

(2012) Giannicola Genovese et al.   CELL CYCLE

A Focus on PD-L1 in Human Melanoma

(2012) P. Hersey et al.   CLINICAL CANCER RESEARCH

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

(2012) C. Qian et al.   CLINICAL CANCER RESEARCH

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Functions of DNA methylation: islands, start sites, gene bodies and beyond

(2012) Peter A. Jones   NATURE REVIEWS GENETICS

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Epigenetic Readers in Cancer

(2012) Mark A. Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Beta-catenin inhibits melanocyte migration but induces melanoma metastasis

(2012) S J Gallagher et al.   ONCOGENE

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors

(2012) A S Little et al.   ONCOGENE

Cancer-Type Regulation of MIG-6 Expression by Inhibitors of Methylation and Histone Deacetylation

(2012) Yu-Wen Zhang et al.   PLoS One

A Combination of H2A.Z and H4 Acetylation Recruits Brd2 to Chromatin during Transcriptional Activation

(2012) Ryan Draker et al.   PLoS Genetics

Mutant BRAF Melanomas—Dependence and Resistance

(2011) Poulikos I. Poulikakos et al.   CANCER CELL

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

(2011) F. Su et al.   CANCER RESEARCH

Inhibition of Histone Lysine Methylation Enhances Cancer-Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer

(2011) M. Rao et al.   CANCER RESEARCH

Combinatorial Patterning of Chromatin Regulators Uncovered by Genome-wide Location Analysis in Human Cells

(2011) Oren Ram et al.   CELL

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

(2011) L Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Readers of histone modifications

(2011) Miyong Yun et al.   CELL RESEARCH

Regulation of chromatin by histone modifications

(2011) Andrew J Bannister et al.   CELL RESEARCH

Apoptosis and oncogenesis: give and take in the BCL-2 family

(2011) Fabien Llambi et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase

(2011) Marialuisa Sensi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells

(2011) K J Basile et al.   ONCOGENE

HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells

(2011) Chia-Wei Chou et al.   PLoS One

SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells

(2010) Jiri Vachtenheim et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

BRG1 expression is increased in human cutaneous melanoma

(2010) H. Lin et al.   BRITISH JOURNAL OF DERMATOLOGY

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

FOXD3 Is a Mutant B-RAF–Regulated Inhibitor of G1-S Progression in Melanoma Cells

(2010) Ethan V. Abel et al.   CANCER RESEARCH

A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth

(2010) Alexander Roesch et al.   CELL

HDAC4 inhibits the transcriptional activation of mda-7/IL-24 induced by Sp1

(2010) Lina Pan et al.   Cellular & Molecular Immunology

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

(2010) Michael Dickinson et al.   INVESTIGATIONAL NEW DRUGS

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT

(2010) Francesca Bruzzese et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The histone variant macroH2A suppresses melanoma progression through regulation of CDK8

(2010) Avnish Kapoor et al.   NATURE

Suppression of inflammation by a synthetic histone mimic

(2010) Edwige Nicodeme et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer

(2010) Steffen Wedel et al.   PROSTATE

Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS

(2010) C C Jiang et al.   Cell Death & Disease

Small molecules and targeted therapies in distant metastatic disease

(2009) P. Hersey et al.   ANNALS OF ONCOLOGY

Treatment combinations targeting apoptosis to improve immunotherapy of melanoma

(2009) Peter Hersey et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity

(2009) Cristina Garrido et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Mitogen-Activated Protein Kinase Inhibition Induces Translocation of Bmf to Promote Apoptosis in Melanoma

(2009) M. W. VanBrocklin et al.   CANCER RESEARCH

Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824

(2009) D. D. Vo et al.   CANCER RESEARCH

HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression

(2009) X. Huang et al.   CANCER RESEARCH

Loss of SNF5 Expression Correlates with Poor Patient Survival in Melanoma

(2009) H. Lin et al.   CLINICAL CANCER RESEARCH

BRAF Signaling and Targeted Therapies in Melanoma

(2009) Nathalie Dhomen et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

(2009) Evanthia Galanis et al.   JOURNAL OF CLINICAL ONCOLOGY

The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a

(2009) Therese M Becker et al.   Molecular Cancer

Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis

(2009) K. Boisvert-Adamo et al.   MOLECULAR CANCER RESEARCH

Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma

(2009) B Keenen et al.   ONCOGENE

Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors

(2008) A. F. Setiadi et al.   CANCER RESEARCH

Transcriptional Modulation Using HDACi Depsipeptide Promotes Immune Cell-Mediated Tumor Destruction of Murine B16 Melanoma

(2008) Takashi Murakami et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Active N-Ras and B-Raf Inhibit Anoikis by Downregulating Bim Expression in Melanocytic Cells

(2008) Nathaniel B. Goldstein et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

(2008) Alejandro Villagra et al.   NATURE IMMUNOLOGY

Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage

(2008) Satoru Yokoyama et al.   Pigment Cell & Melanoma Research

Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival

(2008) Robert A. Cartlidge et al.   Pigment Cell & Melanoma Research

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?

(2008) Jerry E. Chipuk et al.   TRENDS IN CELL BIOLOGY

Regulation of protein turnover by acetyltransferases and deacetylases

(2007) Karin Sadoul et al.   BIOCHIMIE